-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
Celtic Bank Selects Infinant to Scale Its Embedded Finance Programs
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
-
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Long Island Capital Alliance to Host Technology Capital Forum
-
BlackBerry and Hazard Management Cayman Islands Renew Critical Alerting System for Emergencies and Public Safety
-
Medical Care Technologies Inc. (OTCID:MDCE) Pauses Dilution Through 2027 After Q3 Profitability Rebound and Infinite Auctions Private Sales Exceed $300,000 in Q4
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Nextech3D.ai Reports Fiscal Q2 2027 Financial Results: AI Event Technology Doubles Revenue
-
Who Is the Best MTF Top Surgeon?
-
Kolter Homes Introduces New Nancy Floorplan at Woodland Preserve in Parrish, Florida
Hemogenyx Pharmaceuticals PLC Signs Letter of Intent
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in Estonia
First Potential Near-Term Revenue Opportunity
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in Estonia
First Potential Near-Term Revenue Opportunity
LONDON / ACCESS Newswire / September 23, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has signed a Letter of Intent ("LOI") with Cellin Technologies OÜ ("Cellin"), a leading Estonian cell therapy company, to explore the commercialization of the Company's HG-CT-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia ("R/R AML") through the hospital exemption pathway under Estonia's Medicinal Products Act. This collaboration represents the first potential near-term revenue opportunity for HG-CT-1.
The hospital exemption pathway, as amended by the Estonian government in April 2025, permits the use of certain advanced therapy medicinal products ("ATMPs") that have not yet been authorized for commercial marketing to treat an unlimited number of patients, subject to sufficient preclinical or Phase I clinical trials data. The scheme also allows innovators to apply for reimbursement of treatment costs through the Estonian National Health Fund. This framework offers Hemogenyx Pharmaceuticals the opportunity to generate early revenue from HG-CT-1 while simultaneously expanding the body of real-world clinical data to complement its ongoing Phase I trial.
Under the LOI:
Hemogenyx Pharmaceuticals will retain full ownership of all intellectual property, know-how, data and regulatory rights relating to HG-CT-1 and will be entitled to revenues from commercialization.
Cellin will act as Hemogenyx Pharmaceuticals' local partner in Estonia, providing manufacturing, regulatory, and operational support, including securing permits from the Ministry of Health and facilitating administration of the therapy through attending physicians. Cellin will receive fair compensation for its services, to be defined in subsequent definitive agreements.
The LOI is non-binding and serves as a framework for further discussions between the parties. Binding commitments will be established only upon execution of definitive agreements.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, said:
"Our first priority is to save the lives of patients with relapsed or refractory AML, for whom treatment options remain scarce. Building on this mission, the partnership with Cellin also creates a path to generate initial revenues from HG-CT-1 under Estonia's hospital exemption pathway, while providing valuable real-world patient data to complement our Phase I trial and support the future development and commercialization of the therapy."
Ivari Saar, Board Member of Cellin Technologies, said:
"We are thrilled to partner with Hemogenyx Pharmaceuticals to bring next-generation CAR-T therapy to Estonia, marking a major milestone for patients with acute myeloid leukemia and other hard-to-treat blood cancers. This collaboration positions Estonia at the forefront of advanced cell therapy in Europe, combining scientific innovation with a commitment to accessible care. Together, we aim to demonstrate how CAR-T can deliver transformative outcomes for patients across the EU."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
About Cellin Technologies OÜ
Cellin Technologies has established itself as a leading Baltic player in bringing advanced cell therapies to patients, supported by recent reforms in Estonia's hospital exemption legislation. Its lead program, AngioARC, an autologous MSC-based therapy, has already shown encouraging clinical outcomes under this pathway. Cellin's integrated infrastructure spans the full value chain, from R&D laboratories to technology transfer and GMP-compliant manufacturing, ensuring rapid and reliable scale-up.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
S.Jackson--AT